Andrew J. Bannister

University of Technology Sydney — Australia

Biochemistry, Genetics and Molecular Biology · Life Sciences

60h-index32.4kcitations132works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genomics and Chromatin Dynamics(38), Epigenetics and DNA Methylation(35), Ubiquitin and proteasome pathways(28), Protein Degradation and Inhibitors(28), Cancer-related gene regulation(22)

Publications132 total

Matrix directs trophoblast differentiation in a bioprinted organoid model of early placental development
Nature Communications·2025· 4 citedOpen Access
METTL9 sustains vertebrate neural development primarily via non-catalytic functions
Nature Communications·2025· 3 citedOpen Access
METTL9 sustains vertebrate neural development primarily via non-catalytic functions
2025Open Access
Dynamic histone modification patterns coordinating DNA processes
Molecular Cell·2025· 17 cited
THUMPD3 regulates alternative splicing of ECM transcripts in human lung cancer cells and promotes proliferation and migration
PLoS ONE·2024· 2 citedOpen Access
PhOxi-seq Detects Enzyme-Dependent m <sup>2</sup> G in Multiple RNA Types
ACS Chemical Biology·2024
PhOxi-seq detects enzyme-dependent m <sup>2</sup> G in multiple RNA types
2024· 1 citedOpen Access
Editorial: Colyn Crane-Robinson (1935–2023)
Nucleic Acids Research·2023Open Access
Supplemental Figures S1-S6 from Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
2023Open Access
Supplemental Methods and References from Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
2023Open Access
Data from Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
2023Open Access
Supplementary Tables S1-S8 from Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
2023Open Access
Data from Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
2023Open Access
Supplementary Tables S1-S8 from Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
2023Open Access
Supplemental Figures S1-S6 from Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
2023Open Access
Supplemental Methods and References from Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
2023Open Access
Histone post-translational modifications — cause and consequence of genome function
Nature Reviews Genetics·2022· 982 cited
BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL
Cancers·2021· 5 citedOpen Access
Molecular mimicry of NF-κB by vaccinia virus protein enables selective inhibition of antiviral responses
Nature Microbiology·2021· 55 citedOpen Access
Phosphorylation-dependent BRD4 dimerization and implications for therapeutic inhibition of BET family proteins
Communications Biology·2021· 23 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Tony Kouzarides(42), Robert Schneider(11), Mark A. Dawson(6), Eric A. Miska(5), Samuel C. Robson(4), Alan G. Hendrick(3), Tom Owen‐Hughes(3), Berthold Göttgens(3), M. Azim Surani(3), A Cook(3), Rab K. Prinjha(3), Janet F. Partridge(2), Robin C. Allshire(2), Helena Santos-Rosa(2), Étienne De Braekeleer(2), Demetrios Aspris(2), Natalie Webster(2), Byron Andrews(2), George S. Vassiliou(2), Konstantinos Tzelepis(2)